WO2007033591A1 - Substance active pour prothese en cas de blessures - Google Patents

Substance active pour prothese en cas de blessures Download PDF

Info

Publication number
WO2007033591A1
WO2007033591A1 PCT/CN2006/002459 CN2006002459W WO2007033591A1 WO 2007033591 A1 WO2007033591 A1 WO 2007033591A1 CN 2006002459 W CN2006002459 W CN 2006002459W WO 2007033591 A1 WO2007033591 A1 WO 2007033591A1
Authority
WO
WIPO (PCT)
Prior art keywords
wound
wounds
weeks
healing
prosthetic material
Prior art date
Application number
PCT/CN2006/002459
Other languages
English (en)
Chinese (zh)
Inventor
Shanshan Xi
Original Assignee
Shanshan Xi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanshan Xi filed Critical Shanshan Xi
Publication of WO2007033591A1 publication Critical patent/WO2007033591A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives

Definitions

  • the present invention relates to a material for treating wounds, and more particularly to a wound repairing material for treating wounds.
  • the dressings used for treating wounds can be divided into traditional dressings, animal dressings, synthetic dressings, biological dressings, drug dressings and fixed dressings according to materials and uses.
  • the research on dressings has been very recent in the past decade.
  • Great progress, but the prior art dressing 1. Can not absorb the wound exudate well, maintain the wound temperature, provide a good local environment for wound healing, actively promote wound healing; 2.
  • the object of the present invention is to provide a wound active repair material, which can effectively promote blood vessel growth, improve local microcirculation of damage, promote cell proliferation and growth factor expression, promote wound healing and reduce scar by the repair material of the present invention. Formed to compensate for the deficiencies in the prior art.
  • the wound active repairing material of the invention is mainly composed of the following components:
  • Hyaluronic acid silicon dioxide, sodium oxide, calcium oxide, phosphorus pentoxide.
  • the main components are composed of the following weight ratios: Hyaluronic acid 3-40%;
  • the composition of the wound active repairing material proposed by the invention is stable, and the silica, sodium oxide, calcium oxide, and phosphorus pentoxide are mixed and pulverized, the particle diameter is not more than 300 um, and then mixed with hyaluronic acid in proportion.
  • the post-made wound-repairing material can be made into powder, paste and plug by reworking.
  • the wound active repairing material of the invention can be used for treating diabetic ulcer acne pressure ulcer, skin and mucosal ulcer and erosive lesion localized degree III degree burn and scald, various surgical and surgical wounds, can not be sutured in stage I. Wounds, surgical incisions that failed to heal on time, gynecological cervical erosion, wound healing after healing of leprosy, unhealthy wounds caused by unknown causes.
  • its main components are comprised of the following weight ratios:
  • the wound active repairing material of the present invention because of its unique surface activity, can increase the local oxygen pressure and pH value when it contacts the soft tissue wound surface, and form a strong surface negative charge, adsorbing fibrin, collagen and Cells, which promote the rapid formation of calcium and phosphorus layers, stabilize these proteins and cells in the wound, and promote wound healing.
  • the patent applicant of the present invention was approved by a relevant state department of the country and carried out in a medical university affiliated hospital in China. Clinical validation.
  • a skin mucosal or soft tissue ulcerative lesions B skin mucosal erosive lesions; C can not be sutured wounds in stage I, surgical incisions that fail to heal on time; localized 11 degree and 111 degree burns or burn wounds ;
  • the age is 12-85 years old, both in the outpatient and inpatient, male or female.
  • the observation period is less than 4 weeks;
  • the selected cases were divided into the experimental group and the control group.
  • the age, condition and wound condition of the two groups were similar.
  • one wound can be selected for treatment observation, and other wounds can be changed according to the conventional method, and self-control can be used.
  • test group disinfection of the wound surface according to the conventional method, remove dirt and necrotic tissue, and cover the wound active repair material, change once a day or every other day; insulin can be placed in the wound of diabetic patients, other patients according to the situation of the wound Enter gentamicin, or saline wet dressing, or oil gauze drainage; etc.; the wounds were evaluated at 72 hours, 1 week, 2 weeks, 3 weeks, and 4 weeks after the first use of the material.
  • Control group According to the above method, the drug was applied without wound wound repair material, and the wound evaluation time was the same as that of the test group.
  • Velocity growth rate The growth rate of granulation is calculated according to the change of wound depth and expressed as a percentage.
  • Efficacy criteria The efficacy is divided into four levels: recovery, markedly effective, effective, and ineffective.
  • the granulation tissue of the wound began to grow in 72 hours, and the fresh granulation tissue increased after 1 week. See Table 7 for comparison with the control group.
  • the wound area of the wound-repairing material began to shrink, and the shrinking speed was the fastest in 2 weeks, and the speed became stable after 2 weeks.
  • the wound area began to shrink at 1 week, accelerated at 3 weeks, and reached the test group level at 4 weeks, as shown in Table 9.
  • the recovery rate of the test group was 9.8% at 1 week, and 46.3% at 2 weeks. Another case was cured after the second stage suture, accounting for 56.1% at 3 weeks. Zhou Shizhan accounted for 75.6%. In the control group, the wounds did not heal within 2 weeks. The cure rate accounted for 14.3% at 3 weeks, and 42.9 at 4 weeks, which was significantly lower than the test group. According to the effective recovery + marked effect, the total efficacy of the two groups is shown in Table 10. .
  • the invention proves that the wound active repairing material of the present invention can promote the healing of soft tissue wounds, the total effective rate is 82.9%, the wound healing rate is 75.6%, and the marked efficiency is 7.3%;
  • the repair material can significantly reduce the wound exudate and promote the growth of granulation tissue. After using this material, more than 64.9% of the cases have fresh granulation tissue, and after 6 weeks, more than 69.4% of the cases, granulation growth rate More than 60%; in the healing of soft tissue wounds, the cure rate was 9.8% at 1 week, 46.3% at 2 weeks, and 3 weeks 56.
  • the present invention has not found any toxic side effects in the experiment, and the wound active repairing material of the present invention has the effect of promoting the healing of soft tissue wounds. Significant therapeutic effect without any side effects.
  • Patient XXX Female 45 years old, suffering from pemphigus vulgaris, half a year, erythema of the whole body, blisters with erosion, obvious exudation, visible oral mucosa, extensive flaky erosion of the gingival area with infection, severe pain, can not eat, difficult Enduring; externally applied wound repairing material, once a day, pain relief after one week, wound granulation tissue is fresh, oozing is reduced, skin lesions are significantly reduced, pain is significantly reduced after two weeks, and the wound is completely dry and healed.
  • Patient XXX female, 73 years old, was hospitalized for 19 days after cerebral hemorrhage. The patient was found to be comatose in the bathroom 22 days ago. The skin on the back shoulder and buttocks was burned and crushed. After the hospital, the dressing was routinely changed, but the wound was never After that, it was changed to regular dressing plus SDAg external application, oil yarn drainage, the effect was not good, after 30 days of admission, the topical wound active repair material was changed, and the wound became more The speed of the joint was obviously accelerated, the wound on the right shoulder was not deep, the wound was completely healed in 4 weeks, the wound on the buttocks was deep, and the granulation color was dark. The granulation tissue was fresh after 1 week of wound dressing repair material plus regular dressing change, and the growth was faster. After 4 weeks The wound healing was more than 85%, which was significantly better than the conventional method of dressing change without any adverse reactions.
  • XXX male, 65 years old, due to the skin of the foreskin glans collapsed for 2 months, check: the back of the glans has a 0. 8 X 1. 5cm 2 ulcer, the inner root of the foreskin has a 2. 0 X 0. 5cm 2 ulcers, ulcer depth 0. 2cm, used 1: 5000PP external washing and oral PPA and other anti-inflammatory drugs, the effect is not obvious, after the use of wound active repair materials, once a day, after 3 days, the exudate disappeared, the wound began to shrink, At 1 week, the granulation tissue was fresh, the wound surface was reduced by 50%, and the ulcer was completely healed at 2 weeks without any adverse reactions.
  • the wound active repairing material of the invention can stimulate the migration, proliferation and differentiation of epidermal cells and fibroblasts, thereby satisfying the requirements of rapid synthesis of matrix and epidermal cover, reducing the circulation resistance of newly repaired blood vessels, hindering the deposition of granulocytes, It inhibits vascular endothelial swelling, reduces the accumulation of cell debris in blood vessels, greatly reduces the blood resistance of blood vessels and the incidence of embolism, thereby improving local microcirculation, tissue repair, promoting blood vessel growth, and the formation of blood vessels for the regeneration of regenerative tissues.
  • wound active repair materials can be used to treat diabetic ulcers, acne, pressure ulcers, skin and mucosal ulcers and erosive lesions, localized degree II and degree burns and Wounds caused by burns, various operations and trauma, wounds that cannot be sutured in stage I, surgical incisions that failed to heal on time, gynecological cervical erosion, wound healing after healing of leprosy, and wounds that are difficult to heal due to unexplained causes.
  • the main components thereof are composed of the following weight ratios:
  • the main components thereof are composed of the following weight ratios:
  • Patient XXX 34 Male due to drug allergy caused by glans erosion, area 1.5X.0cm 2 , depth 0.1, duration of 1 week, after treatment with the above formula products for 4 weeks ⁇ More.
  • Patient XXX 73 Female had a right shoulder ulcer due to burns after accidental fainting. The area was 3X5cm 2 , the depth was lcm, and the course of disease was 54 days. The product of the above formula was cured 6 weeks after treatment.
  • the wound active repairing material of the invention can be made into a powder form, a paste form and a plug shape, and the powder form is a white fine powder, and no impurities visible to the naked eye are required; the paste is white and tasteless; the plug is a white duck. Mouth plug.

Abstract

Cette substance active pour prothèse en cas de blessures est essentiellement composée d'acide hyaluronique, de dioxyde de silicium, d'oxyde de sodium, d'oxyde de calcium et de pentoxyde de phosphore. Cette substance favorise des mouvements des cellules de l'épiderme et des fibroblasts, réduit la résistance de circulation dans les vaisseaux sanguins nouveaux, empêche le dépôt de granulocytes, limite la tuméfaction du tissu endothélial, diminue l'accumulation de déchets cellulaires dans les vaisseaux et réduit considérablement la résistance sanguine et l'apparition d'embolisme dans les microvaisseaux de manière à améliorer la microcirculation locale et la réparation des tissus dans le but de favoriser la croissance des vaisseaux sanguins. La substance de la prothèse peut être appliquée pour traiter des ulcères diabétiques, des escarres de décubitus, des ulcères cutanés et des membranes muqueuses et des maladies vésicantes, des brûlures et des échaudures locales de deuxième et troisième degré, différentes lésions causées par une opération et un traumatisme, les blessures non suturées au niveau I, des incisions chirurgicales n'ayant pas cicatrisé dans une période idéale, les érosions cervicales, la cicatrisation après guérison de la lèpre et les blessures difficiles à guérir pour des raisons encore inconnues.
PCT/CN2006/002459 2005-09-22 2006-09-20 Substance active pour prothese en cas de blessures WO2007033591A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005101049162A CN100502953C (zh) 2005-09-22 2005-09-22 创面活性修复材料
CN200510104916.2 2005-09-22

Publications (1)

Publication Number Publication Date
WO2007033591A1 true WO2007033591A1 (fr) 2007-03-29

Family

ID=37888549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/002459 WO2007033591A1 (fr) 2005-09-22 2006-09-20 Substance active pour prothese en cas de blessures

Country Status (2)

Country Link
CN (1) CN100502953C (fr)
WO (1) WO2007033591A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6091415B2 (ja) * 2010-10-07 2017-03-08 ナショナル チェン クン ユニバーシティー 糖尿病における虚血肢の血流の促進のためのヒアルロナンの使用
CN104258453A (zh) * 2014-09-24 2015-01-07 湖北华中医用材料有限公司 一种活性创面修复材料的原料组合物及制备方法
CN104324410A (zh) * 2014-09-26 2015-02-04 湖北华中医用材料有限公司 一种多组分活性创面修复材料的原料组合物及制备方法
CN105169458A (zh) * 2015-09-25 2015-12-23 胡方 生物活性矿物质材料及其在软组织溃疡、长期糜烂、伤口细胞再生和抑制黑素瘤的应用
CN109513037B (zh) * 2018-11-14 2021-09-17 华中科技大学同济医学院附属协和医院 一种负载介孔生物玻璃的小肠粘膜下层创面敷料

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604200A (en) * 1994-05-02 1997-02-18 Taylor-Mccord; Darlene Wound therapeutic mixture containing medical grade hyaluronic acid and tissue culture grade plasma-fibronectin in a delivery system that creates a moist environment which simulates in utero healing
US6262020B1 (en) * 2000-02-15 2001-07-17 Alphamed Pharmaceuticals Corp. Topical wound therapeutic compositions
US6517863B1 (en) * 1999-01-20 2003-02-11 Usbiomaterials Corporation Compositions and methods for treating nails and adjacent tissues
CN1136012C (zh) * 2000-08-07 2004-01-28 黄玲惠 伤口敷料及其制备方法
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604200A (en) * 1994-05-02 1997-02-18 Taylor-Mccord; Darlene Wound therapeutic mixture containing medical grade hyaluronic acid and tissue culture grade plasma-fibronectin in a delivery system that creates a moist environment which simulates in utero healing
US6517863B1 (en) * 1999-01-20 2003-02-11 Usbiomaterials Corporation Compositions and methods for treating nails and adjacent tissues
US6262020B1 (en) * 2000-02-15 2001-07-17 Alphamed Pharmaceuticals Corp. Topical wound therapeutic compositions
CN1136012C (zh) * 2000-08-07 2004-01-28 黄玲惠 伤口敷料及其制备方法
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair

Also Published As

Publication number Publication date
CN1935267A (zh) 2007-03-28
CN100502953C (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
JP5580896B2 (ja) 糖尿病性潰瘍を処置するための医薬の調製における薬学的組成物の使用
WO2007033591A1 (fr) Substance active pour prothese en cas de blessures
CN101306163A (zh) 止血生肌散
CN107446018B (zh) 促进伤口愈合的肽及其应用
CN109731040A (zh) 一种外伤修复组合物、制备方法及其应用
CN100348202C (zh) 一种治疗皮肤病的口服复方制剂
Banerjee et al. Bees make medicine for mankind
CN105031622A (zh) 一种促进伤口愈合的药物组合物及其制备方法
KR101820519B1 (ko) 설글리코타이드의 피부 상처 치유 촉진 용도, 및 이를 포함하는 외용제 조성물
WO2009027823A2 (fr) Composition pharmaceutique pour une stimulation sélective de procédés de cicatrisation de lésion, de procédés de tropisme tissulaire normal dermique-épidermique, sa préparation et son application
CN101380349A (zh) 一种烧伤、烫伤特效药膏
CN108635362B (zh) 一种治疗糖尿病足的药物组合物
CN117138028B (zh) 一种含有表皮干细胞因子的组合物及其在糖尿病足修复中的应用
CN101028365A (zh) 一种治疗烧、烫伤的药物及其制备方法
CN104800280A (zh) 糖尿病手足伤口愈合中药膏及制备方法
CN104189304A (zh) 一种用于治疗外科伤口的中药组合物及其制备方法
TWI610674B (zh) 一種用於促進傷口癒合或預防、減少傷口疤痕生成的醫藥組合物
CN108785530A (zh) 一种液化生肌愈皮膏及其制备方法
Kirby et al. Treatment of osteomyelitis of the facial bones with penicillin
CN101057823A (zh) 一种具有抗衰老及美容作用的复合生物制剂
JP2004523521A (ja) 非代謝性の糖質と高分子吸収剤とを用いた細胞再生及び／又は細胞分化の促進
CN117138029B (zh) 一种含有表皮细胞因子的组合物及其在褥疮修复中的应用
CN111317853B (zh) 一种防治褥疮的敷料及其制备方法
KR20170098676A (ko) 피부 외상 치료용 중국 의약
AU2017255833A1 (en) Application of small-molecule hyaluronic acid fragment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06791050

Country of ref document: EP

Kind code of ref document: A1